Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-cell (CAR-T) Therapy: Recognition, Risk Factors, and Management
Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of non-Hodgkin Lymphoma. As this treatment is being increasingly utilized, a better understanding of the unique toxicities as...
Main Authors: | Ethan A. Burns, Cesar Gentille, Barry Trachtenberg, Sai Ravi Pingali, Kartik Anand |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Diseases |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-9721/9/1/20 |
Similar Items
-
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
by: Riegler LL, et al.
Published: (2019-02-01) -
Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
by: Felix Korell, et al.
Published: (2021-04-01) -
Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report
by: Antonina E. Shchekina, et al.
Published: (2021-07-01) -
Osimertinib-Induced Cardiotoxicity
by: Kartik Anand, MD, et al.
Published: (2019-12-01) -
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
by: Guoqing Wei, et al.
Published: (2017-04-01)